Search This Blog

Wednesday, June 15, 2016

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (NYSE:LLY)

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.